Podcasts about Cart

Would You Swap the Noisy Cart by Maine's Coast 93.1

On today episode, Andy & DJ discuss ICE rolling Portland protester away on flatbed cart as Trump says city is burning to the ground, a bloody Mark Sanchez seen stumbling down Indianapolis sidewalk after being stabbed in fight with grease truck driver, and a brand new segment of AI or Nah.

Welcome to Omni Talk's Retail Daily Minute, sponsored by Mirakl. In today's Retail Daily Minute, Omni Talk's Chris Walton discusses:Rite Aid closes all remaining stores, ending 63 years in business after two bankruptcies and selling pharmacy services to CVS, Walgreens, and other rivals.Shipt partners with Perplexity to launch an AI-powered chat-to-cart feature through Comet browser.Amazon shutters four more Amazon Fresh stores in Southern California, continuing its strategic pullback from underperforming grocery locations.And, my “One Big Thought” for the day on generative AI eventual impact on grocery.The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights. Be careful out there!

Broadcast from KSQD, Santa Cruz on 10-02-2025: Dr. Dawn opens by explaining how blood pressure treatment guidelines have been corrected back to 140/90 after the problematic 2015 SPRINT study temporarily changed recommendations to 120/80. That study used ideal measurement conditions - five minutes of quiet sitting, perfect cuff sizes, compliant patients - creating unrealistic targets that caused elderly patients to faint and break hips. The Veterans Administration and major cardiology organizations now recommend treating to 140/90, with statins only for LDL above 190 or 12% ten-year cardiovascular risk. An emailer asks about claims linking Tylenol to autism. Dr. Dawn thoroughly debunks this, explaining that Swedish studies of 2.5 million children found no association when controlling for sibling comparisons. She notes autism rates remained flat from 1960-1990 despite widespread Tylenol use, then spiked after DSM-4 in 1994 and DSM-5 in 2013 broadened diagnostic criteria. Recall bias skews studies since mothers of autistic children are asked leading questions about past Tylenol use during pregnancy when fever treatment was medically necessary. She discusses RFK Jr.'s mixed positions, comparing him to Isaac Newton who excelled at physics but believed in astrology. While criticizing vaccine misinformation, Dr. Dawn strongly supports RFK's stance on ultra-processed foods. She describes NIH researcher Kevin Hall's studies showing people consume 500 extra calories daily on ultra-processed diets versus whole foods, even when nutrients are matched. The US produces 15,000 calories per person daily, with the food industry engineered to promote overconsumption through hyper-palatable fat-sugar-salt combinations. A caller asks about Healthcare 4.0 plans for biometric tracking bracelets and digital twins. Dr. Dawn discusses privacy concerns around constant health monitoring and data collection, noting that while early disease detection could be valuable, mandatory participation raises serious civil liberties issues. She acknowledges voluntary research projects like the Million Man Study but emphasizes the importance of consent and protection against unauthorized data access by advertisers or government agencies. An emailer shares research on ultrasound brain stimulation helmets as alternatives to surgical electrode implants. Dr. Dawn explains how 256-element phased ultrasonic arrays can target brain regions like the visual cortex with high precision mechanical perturbation, potentially treating Parkinson's, Alzheimer's, and depression without surgery. The technology remains experimental, requiring MRI guidance, but could become portable and dramatically improve quality of life for neurological conditions currently requiring invasive deep brain stimulation. A caller with adrenal cancer asks about fasting-mimicking diets. Dr. Dawn explains that 14-hour fasting before chemotherapy improves outcomes because healthy cells can downshift metabolism while cancer cells cannot. Cancer cells rely only on glycolysis without mitochondrial function, making them vulnerable during fasting states. She recommends chronotherapy - scheduling treatments during fasting periods - and expresses optimism about new cancer therapies like CAR-T cells and CRISPR technologies. An emailer asks about inulin fiber for fatty liver disease. Dr. Dawn explains how this fiber found in chicory, Jerusalem artichokes, and root vegetables stimulates gut bacteria to break down fructose before it reaches the liver, preventing fructose-induced hepatic lipogenesis. Inulin supplementation protects against fatty liver disease, increases antioxidant production, and helps with obesity by reshaping the gut microbiome to better process dietary sugars.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "ECTRIMS 2025 Meeting Highlights and Clinical Takeaways," Daniel Ontaneda, MD, PhD, neurologist at Cleveland Clinic's Mellen Center for MS, shared his reflections from the 2025 ECTRIMS Congress, held September 24-26, in Barcelona, Spain. He discussed the significance of the updated MS diagnostic criteria, which generated immediate research applications and clinician discussion early in the meeting. Ontaneda also highlighted the growing emphasis on precision medicine and individualized treatment approaches, including extended-interval dosing strategies for B-cell therapies. In addition, he reviewed new therapeutic developments such as BTK inhibitors, CAR-T therapies, and remyelination research, noting both promising and disappointing data. Finally, he spoke on how ECTRIMS continues to expand beyond MS, with more presentations dedicated to NMOSD, MOGAD, and other autoimmune neurological conditions, reflecting the evolving landscape of neuroimmunology. Looking for more Multiple Sclerosis discussion? Check out the NeurologyLive® Multiple Sclerosis clinical focus page. Episode Breakdown: 1:00 – Overall impressions of ECTRIMS 2025, highlighting diagnostic updates, precision medicine, and late-breaking trial results 4:10 – Expanding focus on individualized care, especially interval-adjusted dosing strategies for B-cell therapies 7:50 – Neurology News Minute 9:50 – Insights on emerging therapeutic approaches including BTK inhibitors, CAR-T therapies, and remyelination strategies 14:35 – Growing attention toward NMOSD, MOGAD, and other autoimmune conditions within neuroimmunology discussions The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Scott's old Mr. Show buddy Bob Odenkirk returns to talk about Comic Relief 8, the finale of Better Call Saul, and his future focusing on himself. Then, celebrity chef Bobby Flay stops by to talk about his new cooking show. Plus, lawyer Italiano Jones returns to fight for Scott in a mock trial. Originally released as episode 769 on 08/07/2022. Don't forget to check out the Comedy Bang! Bang! Action Figures at shop.figurecollections.com and go to actionfigureseller.com for international purchases. If you want more great episodes of Comedy Bang! Bang! become a subscriber at comedybangbangworld.com. We have all of the past episodes from the archives, every live show, ad-free new episodes, and original shows like CBB Presents and Scott Hasn't Seen. Find more great Comedy Bang! Bang! merch at https://www.podswag.com/collections/comedy-bang-bang Get access to all the podcasts you love, music channels and radio shows with the SiriusXM App! Get 3 months free using this show link: https://siriusxm.com/cbb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.Featured ArticlesMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trialMatched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack of well-matched donors, and limited gene therapy availability. They emphasize the importance of early referral to specialized centers and the need for discussions about curative intent therapies, including transplant and gene therapy. The conversation also covers the complexities of gene therapy, such as the need for better conditioning agents and the challenges of achieving full correction in all cell types.

The shift from being a "channel" to the leading "Marketplace", this is the future and Jordan shared his expertise, a must listen especially with Shopify's Chatgpt announcements this week. Jordan Brannon from Coalition Technologies discusses the evolving landscape of AI marketing, particularly the integration of AI and the importance of marketplaces and zero party data. He emphasizes the value of quizzes and surveys in capturing customer insights, which can enhance marketing strategies and improve customer experiences. The discussion also covers the challenges of cart abandonment and the future of marketplaces as they adapt to AI-driven consumer behavior.Takeaways:-AI is transforming digital marketing into a marketplace.-Quizzes and surveys provide valuable customer insights.-Zero party data is essential for personalized marketing.-Understanding customer feedback can enhance user experience.-Cart abandonment is often due to poor checkout processes.-AI can optimize marketing strategies effectively.-The future of e-commerce will focus on loyalty and relationships.-Shopify's integration with AI is a game changer.-Consumer behavior insights drive marketing success.-Effective marketing requires understanding and adapting to AI trends.Chapters00:56 The Value of Quizzes and Surveys08:37 Leveraging Zero Party Data for Marketing10:20 Unlocking Marketing Insights Through Data11:02 The Power of Quizzes and Surveys12:03 Leveraging AI for Content Creation13:38 Zero-Party Data and AI Strategies15:24 Optimizing Marketing Campaigns17:04 Building Effective Surveys19:08 Consumer Behavior and AI Insights21:32 Understanding Cart Abandonment24:08 Shopify's Role in E-commerce25:29 The Future of Marketplaces and AI29:37 Free Analytics Dashboard Offer

Nous ouvrons l’émission avec Abdoul Rachid Bagagnan, étudiant en Sciences du Langage à l’Université de Tours, anciennement technicien à la radio Radio Fémina de Ouagadougou, Burkina Faso. Puis : Validé – Le Petit Traité du Silence de Pascal Bataille ; une chronique proposée par Estelle Fageon. Émission en partenariat avec l’INSERM Grand-Ouest Place ensuite à […] L'article La Méridienne – INSERM – Hémopathies malignes et CAR-T cells est apparu en premier sur Radio Campus Tours - 99.5 FM.

Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.

Alessandro Zanardi, pilote italien au destin hors norme, marque l'histoire du sport automobile avec un dépassement légendaire à Laguna Seca en 1996, connu comme The Pass. Après une carrière difficile en F1, il triomphe en CART aux États-Unis. Mais en 2001, un terrible accident lui coûte ses deux jambes. Miraculé, il survit contre toute attente. Il revient au volant, gagne des courses, puis entame une carrière en handisport. Il remporte 4 médailles d'or paralympiques et devient un symbole mondial de résilience. En 2020, il est à nouveau gravement blessé dans un accident. Toujours vivant, Zanardi incarne la force, la foi et le refus d'abandonner. Une vie défiant la fatalité. Merci pour votre écoute Vous aimez l'Heure H, mais connaissez-vous La Mini Heure H https://audmns.com/YagLLiK , une version pour toute la famille.Retrouvez l'ensemble des épisodes de l'Heure H sur notre plateforme Auvio.be :https://auvio.rtbf.be/emission/22750 Intéressés par l'histoire ? Vous pourriez également aimer nos autres podcasts : Un jour dans l'Histoire : https://audmns.com/gXJWXoQL'Histoire Continue: https://audmns.com/kSbpELwAinsi que nos séries historiques :Chili, le Pays de mes Histoires : https://audmns.com/XHbnevhD-Day : https://audmns.com/JWRdPYIJoséphine Baker : https://audmns.com/wCfhoEwLa folle histoire de l'aviation : https://audmns.com/xAWjyWCLes Jeux Olympiques, l'étonnant miroir de notre Histoire : https://audmns.com/ZEIihzZMarguerite, la Voix d'une Résistante : https://audmns.com/zFDehnENapoléon, le crépuscule de l'Aigle : https://audmns.com/DcdnIUnUn Jour dans le Sport : https://audmns.com/xXlkHMHSous le sable des Pyramides : https://audmns.com/rXfVppvVous aimez les histoires racontées par Jean-Louis Lahaye ? Connaissez-vous ces podcast?Sous le sable des Pyramides : https://audmns.com/rXfVppv36 Quai des orfèvres : https://audmns.com/eUxNxyFHistoire Criminelle, les enquêtes de Scotland Yard : https://audmns.com/ZuEwXVOUn Crime, une Histoire https://audmns.com/NIhhXpYN'oubliez pas de vous y abonner pour ne rien manquer.Et si vous avez apprécié ce podcast, n'hésitez pas à nous donner des étoiles ou des commentaires, cela nous aide à le faire connaître plus largement. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Episode 478: I will discuss The Lytton's Department Store and read a 1963 menu from The Cart Restaurant in Chicago.

Episode 478: I will discuss The Lytton's Department Store and read a 1963 menu from The Cart Restaurant in Chicago.

HOUR 1- Cart Edging, ADD News and MORE full 2194 Fri, 26 Sep 2025 15:42:00 +0000 lCIjlYhz38SD10exomZMpTfs1zeKBDEo society & culture Klein/Ally Show: The Podcast society & culture HOUR 1- Cart Edging, ADD News and MORE Klein.Ally.Show on KROQ is more than just a "dynamic, irreverent morning radio show that mixes humor, pop culture, and unpredictable conversation with a heavy dose of realness." (but thanks for that quote anyway). Hosted by Klein, Ally, and a cast of weirdos (both on the team and from their audience), the show is known for its raw, offbeat style, offering a mix of sarcastic banter, candid interviews, and an unfiltered take on everything from culture to the chaos of everyday life. With a loyal, engaged fanbase and an addiction for pushing boundaries, the show delivers the perfect blend of humor and insight, all while keeping things fun, fresh, and sometimes a little bit illegal. 2024 © 2021 Audacy, Inc. Society & Culture False https://player.amperwavepodcasting.com?feed-link=https

Chris Walton explains why he doesn't think grocers should be prioritizing smart cart investments.Brought to you with the help and support of Mirakl - The catalyst of commerce. Over 450 retailers are opening new revenue streams with marketplaces, dropship, and retail media. Unlock more products, more partners, and more profits without the heavy lifting. Visit Mirakl.com to learn more.Hosted by Chris Walton, former Target executive and co-host of the Omnii Talk Retail Fast Five Podcast. New episodes of Walton's Weekly Wramblings drop every Friday.Subscribe now and be careful out there - the retail landscape is changing faster than ever.

In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing resistance.

In this week's episode, we'll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize the presence of two or more high-risk cytogenetic abnormalities.Featured Articles:Association of Epstein-Barr virus genomic alterations with human pathologiesClinical significance of preleukemic somatic GATA1 mutations in children with Down syndromeBiallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

For decades, Dr. Bruce Levine has been at the forefront of cancer research, pioneering CAR T-cell therapy—a treatment that harnesses a patient’s own immune system to fight cancer. On a recent conversation with Asia Tabb, Levine shared his journey and the promise of this innovative therapy.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

In today's episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibitors in the management of CLL. He highlighted the importance of molecular profiling for treatment rechallenge decisions and the potential for resistance mutations in this disease. He also noted the role of pirtobrutinib (Jaypirca) in overcoming treatment resistance, along with clinical signs indicating that patients may need a therapy change. Dr Dean also mentioned the high response rates seen with CAR T-cell therapy in patients with CLL and explained the possibility for combination regimens in CLL. Additionally, he expressed optimism about BTK degraders and bispecific antibodies.

Tras 12 años de lucha contra el cáncer (linfoma folicular) y seis tratamientos fallidos, Laurie Adami estuvo a punto de morir. Hasta que una terapia experimental cambió su historia: las células CAR T. En este episodio, el testimonio de Adami se entrelaza con la voz de expertos internacionales para entender cómo funciona dicha terapia, cuáles son sus riesgos y, sobre todo, los retos y soluciones de hacerla accesible en países como México. En este episodio entrevistamos a: Alejandro Madrigal, José Carlos Crispín de la Escuela de Medicina y Ciencias del Tec de Monterrey y a María Eugenia Fernández Santos de La Red Española de Terapias Avanzadas.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and how to manage common adverse events. Joining Dr. Charles Turck to explore how CAR T fits into the broader treatment algorithm for follicular lymphoma is Dr. Jonathan Cohen. Not only is he a Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, but he's also the Co-Director of the Lymphoma Program at the Winship Cancer Institute of Emory University in Atlanta.

In this episode, we preview ACR Convergence 2025 in Chicago this October with Dr. Greg Gardner, Chair of the Annual Meeting Planning Committee (AMPC). We'll explore key topics like emerging therapies, AI in rheumatology, and highlights such as the Practice Innovation Summit, Ultrasound Course, and Fellows In Training (FiT) Program. Dr. Gardner also discusses highlights such as, CAR T-cell therapies, new non-renal lupus guidelines, a Live Journals Club focused on Big Data and why this year's meeting is earlier on the calendar. Tune in for a sneak peek at what's to come! 

Pedro Fernando Nery, colunista do Estadão, professor de economia do IDP (Instituto Brasileiro de Ensino, Desenvolvimento e Pesquisa), analisa a Economia interna, às 3ªs, 7h45, no Jornal Eldorado.See omnystudio.com/listener for privacy information.

From Ice Cream Cart to National Brand - The Hazel's Ice Cream StoryIn this episode, hosts Kenny and Phil sit down with Sam Vermeulen, co-founder of Hazel's Ice Cream, to discuss the remarkable journey from a COVID-era ice cream cart idea to a growing national frozen novelty brand.Sam shares how what started as a father-son dream of running an ice cream shop evolved into handcrafted premium ice cream bars. Born out of necessity during the pandemic, Hazel's pivoted from scooped ice cream to bars when traditional retail wasn't an option - a decision that accidentally filled a market gap in Victoria's frozen novelty scene.

This month, the gals invite Steven Ray Morris on to gab about cats in baskets, pettiness with a capital “pee,” the cutest little classroom assistant, unicorn permits, chimp fads, and Lucy's really cool great aunt. Tune in now for September's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

[STRATEGY SHIFT] In this behind-the-scenes solo episode of Business Not As Usual, I'm sharing the exact strategies that helped me sign more than half the spots for The Distinctive Edge before the cart even opened. Here's what you'll hear inside: The truth about strategic private invites (and why most people do them wrong). How to use self-identifier content to spark conversations and sign clients without “selling.” The $47 low-ticket workshop that turned into $20K in sales (and why it works so well). Why none of these tactics matter without a clear Distinctive Edge: your unique perspective and framework. A raw look at how I'm attempting to balance launch week while solo momming my twins. If you've been relying only on content to sell your offers, this episode will show you what's really happening behind the curtain, and how you can replicate it.

Recorded from the cottage (hello, geese + dogs

In this conversation, Erik and Stefan discuss the importance of email marketing in e-commerce, focusing on strategies for cart and checkout abandonment. They explore the current market conditions, the significance of customer experience, and the necessity of implementing effective email automation flows. Stefan shares insights from his experience in the industry, emphasizing the need for businesses to start with the basics and gradually build their email marketing strategies to enhance customer retention and drive revenue.TakeawaysCart abandonment emails are a significant revenue source.Understanding customer behavior is key to effective marketing.New customer flows help build long-term relationships.Focus on customer experience to improve retention rates.Implementing basic email flows can drive immediate results.Testing and optimizing email strategies is crucial for success.Personalization in emails can enhance customer engagement.Utilizing pop-ups effectively can grow email lists.Start with the fundamentals before exploring advanced strategies.Chapters00:00 Introduction and Background04:16 Market Conditions and Email Marketing Trends09:51 The Importance of Cart Abandonment Emails15:48 Strategies for Effective Email Automation20:48 The Importance of Value Exchange in Marketing22:00 Understanding Client Needs and Unique Selling Points24:24 Client Engagement and Building Client Intelligence25:38 Email Automation Strategies for E-commerce27:06 Growing Email Lists and Subscriber Engagement31:12 Identifying High Intent Visitors for Better Conversion34:29 The Significance of New Customer Flows44:26 Final Thoughts on Implementation and Best Practices

Salut les sportifs intelligents ! Cette semaine, on démonte une idée reçue qui empêche beaucoup de gens de perdre du poids : croire qu'il faut faire ZERO écart alimentaire pour réussir. Dans cet épisode, je t'explique pourquoi c'est une erreur qui mène à la frustration, à l'obsession et souvent à l'abandon. On parle ensemble de la balance calorique, du rôle du déficit calorique (≈ 500 kcal/jour = 3500 kcal/semaine), et surtout de l'importance d'intégrer des repas plaisir pour tenir dans la durée.

In this episode, Dr. Douglas Graham, Chief of the Aflac Cancer and Blood Disorders Center, shares progress in pediatric leukemia and sickle cell disease treatments, the impact of a 30-year partnership with Aflac, and breakthroughs in precision medicine, CAR T-cell therapy, and gene therapy that are reshaping outcomes for children and families.

Featuring an interview with Dr Beth Faiman, including the following topics: Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00) Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19) Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00) Patient eligibility to receive CAR T-cell therapy (13:23) Differentiating among approved CAR T-cell therapies for MM (18:18) Durability of responses to CAR T-cell therapy for MM (24:01) Neurotoxicity with CAR T-cell therapies for MM (26:26) Minimal residual disease monitoring in MM (29:39) Support systems for the management of toxicities associated with CAR T-cell therapy (35:10) Patients with MM experiencing durable responses to CAR T-cell therapy (43:11) NCPD information and select publications

Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.

A leading New Zealand research institute is passing the hat to fund the final stages of a clinical trial into a cutting edge treatment for blood cancers. The Malaghan Institute is currently doing clinial trials for CAR-T cell therapy for blood cancer, non-hodgkin lymphoma, with the hope of making it accessible in the public health system. Malaghan Institute Clinical Director, Doctor Robert Weinkove spoke to Lisa Owen.

See omnystudio.com/listener for privacy information.

Sports with Rod 9-18-2025 …These Golfers need a Cart …Tom Brady should pretend he's not Coaching the Raiders …Thinking Inward with Kaleem

The official Sleepers preseason top 25! Who won these college basketball breakups? Which conferences have produced the most NBA talent in the past 3 years? The Sleepers Podcast is now available daily with new episodes every Monday-Friday! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enables extended matching to reduce antibody formation. The results show the potential for reducing harm in regularly transfused patients. Finally, identifying a new vulnerability in TP53-mutated AML. Loss of the tumor suppressor BAP1 defines a unique subtype of TP53-mutated de novo AML. BAP1 loss also confers sensitivity to BCL-xL inhibitors in vivo, opening a new therapeutic avenue.Featured ArticlesEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEXArray genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participantsLoss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

Fall is almost officially here, and we're breaking down the season's must-have beauty products and viral trends – from “toasty” eyeshadow palettes and a soft matte makeup revival to luxe “skin-silking” serums. Plus, our takes on the latest celebrity beauty launches and stay tuned to the end to hear about a $4.99 mascara that we both rate, and a rock-bottom budget acne find from The Ordinary.You'll learn about:The expert-led brands ushering in a whole new beauty era — We test Jennifer Aniston's hairstylist Chris McMillan's Glassy Blowout Spray, the revolutionary “underpainting” palette from Hailey Bieber makeup artist Mary Philips, and the new Eyeshadow Colorstory Palettes by Selena Gomez's pro, Hung VanngoWhat sets Victoria Beckham's splurgy Foundation Drops apart from her contemporaries (hint, Professor Bader's back in the house of Beckham!)First impressions of Martha Stewart's skincare line — and the reason we're not writing it off as just another celebrity line yet The soft matte renaissance— meet Glossier's 2.0 Cloud Paint “Plush” Blush, fluffier powders and “3D matte”Do we really need a $200 snatching serum for those on GLP-1 weight loss medications?! Get social with us and let us know what you think of the episode! Find us on Instagram, Tiktok,X, Threads. Join our private Facebook group. Or give us a call and leave us a voicemail at 1-844-227-0302. Sign up for our Substack here For any products or links mentioned in this episode, check out our website: https://breakingbeautypodcast.com/episode-recaps/

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series. You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart. Episode contents:- What are "CAR T" and "bispecific antibodies"?- What are the approved agents?- Selection of one therapy over another- Side effect profiles**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

CAR-T, een therapie die ziekmakende cellen opruimt, was al veel belovend in kankeronderzoek, maar laat nu ook goede resultaten zien bij het behandelen van auto-immuunziektes. Helaas is de behandeling extreem duur. Ziekenhuizen willen daarom de behandeling zelf maken. Hoe ver zijn ze daarmee? En is genezing met CAR-T mogelijk?Heeft u vragen, suggesties of ideeën over onze journalistiek? Mail dan naar onze redactie via podcast@nrc.nl. Host: Gemma VenhuizenGasten: Karlijn Saris en Sander VoormolenRedactie: Rosa van ToledoZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

We need the audience's help to figure out if Dylan or Robbie is the strange one on the show. Do you keep swim trunks in your trunk just in case there's a swimming emergency? Pepper learns something shocking and disappointing about his daughter's boyfriend. This leads us to find out a rule that could get your Costco membership revoked. What did your parents not allow you to do? We remember some of the bands our moms banned us from listening to. Say it ain't so...it may already be winter tire season...Reminder- there is a special keyword embedded in today's episode where you can win a $500 gift card to Shoppers Drug Mart. Simply text the keyword plus your full name to 917-917. Standard message rates apply. Go to https://www.seekyoursounds.com/contests for contest rules.The Shoppers Beauty+ Event is back at Shoppers Drug Mart! Discover more points, more brands and new and favourite beauty products. Shop in-store or online!

Lola se sent mise à l'écart et en manque de chaleur dans sa relation avec son plus jeune fils, récemment marié. Elle éprouve des difficultés à s'adapter à la nouvelle dynamique familiale, notamment en raison de différences sociales et culturelles avec la belle-famille. Elle cherche à comprendre comment maintenir une relation chaleureuse avec son fils tout en gérant ses propres sentiments de solitude et d'insécurité. Chaque soir, en direct, Caroline Dublanche accueille les auditeurs pour 2h30 d'échanges et de confidences. Pour participer, contactez l'émission au 09 69 39 10 11 (prix d'un appel local) ou sur parlonsnous@rtl.fr.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Vincent travels to Waterville Valley, NH to attend the Harvard virology retreat, where he speaks with Aaron Schmidt, Ben Gewurz, and Tatum Sass about their careers and their research on influenza virus, Epstein-Barr virus, and CAR-T cells. Hosts: Vincent Racaniello Guests: Aaron Schmidt, Ben Gewurz, and Tatum Sass Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Harvard Program in Virology Conserved sites on H1 and H3 HA (Sci Adv) Antigenic drift expands viral escape (Immunity) EBV LMP1 drives B cell oncometabolism (PLoS Path) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Big Al was offended when a guy didn't want to take his cart at the grocery store, and J-Si was up late doing math. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center. In this episode, we covered: • The importance of shared decision-making in CLL treatment. • When to initiate treatment for newly diagnosed CLL patients. • The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors. • Key considerations in choosing the right BTK inhibitor and managing side effects. • The relevance of minimal residual disease (MRD) in treatment duration. • Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice. Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib #CLL2025 #BTKinhibitors #Venetoclax #MRDnegative #OncologyBrothers

Una de las formas de influir en la opinión pública consiste en elegir determinados temas y obviar los que no se ajustan a la línea pastoral del centro. La segunda forma tiene que ver con el tiempo, con los minutos que dedicas a aquello que conviene a los intereses de aquellos que opinan. Dedicarán más y más minutos a machar con una idea, pero si esa idea se revela como falsa, despacharán el asunto de tapadillo, sin darle relevancia alguna, o sencillamente ni lo comentarán. Min. 01 Seg. 50 – Intro Min. 09 Seg. 53 – El perdón de la víctima Min. 16 Seg. 10 – ¡Caramba! No sólo le pasa a Vinicius Min. 26 Seg. 29 – Mentir deliberadamente Min. 33 Seg. 54 – La prueba del engaño Min. 45 Seg. 56 – Una argucia para muy tontos Min. 54 Seg. 52 – Despedida Bruce Hornsby (Richmond, VA 18/05/1996) Stranded On Easy Street Show Goes On Talk Of The Town White Wheeled Limousine Carry The Water The Way It Is Valley Road Roger Hodgson - Had A Dream (Sleeping With The Enemy) (Carcassonne 01/08/2015)

Because it was dude.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This month, the gals invite our wonderful Wisconsinite production manager, Andrea, to discuss flammable turkeys, rats under arrest, a drunken Dells disaster, mystery accents, unearthed urns, and a very creative way of identifying remains. Tune in for August's Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.